CLINICAL_TRIALS
ClinicalTrials.gov record update
Disitamab Vedotin（RC48）Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06185400
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:23.334129+00:00
- Published At
- 2023-12-29T00:00:00+00:00
- Record Updated At
- 2023-12-29
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Non Small Cell Lung Cancer", "ERBB2 Mutation-Related Tumors", "ERBB2 Gene Duplication", "Disitamab Vedotin"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-12-29"- protocolSection.identificationModule.nctId
"NCT06185400"- protocolSection.identificationModule.officialTitle
"Disitamab Vedotin\uff08RC48\uff09Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations"- protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.